目的探讨“基于膜解剖的胃后间隙入路”(我们称之为“欢乐间隙”)联合食管空肠自牵引后离断吻合技术(self-pulling and latter transection,SPLT)在全腹腔镜近端胃切除、双通道吻合术中的应用价值。方法2019年9月~2021年9月,对15例T1~2N...目的探讨“基于膜解剖的胃后间隙入路”(我们称之为“欢乐间隙”)联合食管空肠自牵引后离断吻合技术(self-pulling and latter transection,SPLT)在全腹腔镜近端胃切除、双通道吻合术中的应用价值。方法2019年9月~2021年9月,对15例T1~2N0M0食管胃结合部肿瘤行3D全腹腔镜下近端胃切除、双通道吻合术。“欢乐间隙”为我们基于“膜解剖”理论提出的位于腹腔干左侧、胰腺上后缘的Gerota筋膜与胃背系膜之间的融合筋膜间隙,手术进入此间隙可快速完成胃后部分的分离并完成手术,术者感到愉悦,故称为“欢乐间隙”。使用SPLT技术行食管-空肠吻合。结果15例均顺利完成全腹腔镜手术。手术时间(237.5±55.3)min,术中出血量(84.7±28.3)ml,术后排气时间(2.1±0.4)d,术后进流质饮食时间(2.9±1.1)d,术后引流时间(6.4±0.9)d,总住院时间(15.1±2.1)d。术后病理腺癌11例,高级别上皮内瘤变4例,切缘均为阴性。术后肺部感染2例。随访1年,均未出现反流性食管炎及肿瘤复发,各营养指标变化差异无显著性(P>0.05)。结论“欢乐间隙”入路联合SPLT技术在全腹腔镜近端胃切除、双通道吻合术中安全可行。展开更多
目的:探讨Src酪氨酸激酶抑制剂对人胃癌细胞SGC7901上皮-间质转变相关基因的作用及机制。方法:以Src酪氨酸激酶抑制剂作用前后的SGC7901细胞为研究对象,应用Western blot及real time PCR观察细胞内p-Src及上皮间质转变标志物E-钙黏素(E-...目的:探讨Src酪氨酸激酶抑制剂对人胃癌细胞SGC7901上皮-间质转变相关基因的作用及机制。方法:以Src酪氨酸激酶抑制剂作用前后的SGC7901细胞为研究对象,应用Western blot及real time PCR观察细胞内p-Src及上皮间质转变标志物E-钙黏素(E-cadherin)、β-连环蛋白(β-catenin)表达的变化,报告基因技术检测Snail在转录水平表达的变化。结果:Src酪氨酸激酶抑制剂可上调E-cadherin在mRNA和蛋白水平变化,下调β-catenin在mRNA和蛋白水平变化及Snail的启动子活性。结论:Src酪氨酸激酶抑制剂可抑制人胃癌细胞SGC7901上皮间质转变相关基因表达,其机制可能与其下调SGC7901细胞Snail的启动子活性有关。展开更多
Cinobufacini, a compound extracted from bufo toad, is a traditional Chinese medicine(TCM) that has been shown to have efficacy in cancer treatment.The cinobufacini injection is widely used in patients with moderate an...Cinobufacini, a compound extracted from bufo toad, is a traditional Chinese medicine(TCM) that has been shown to have efficacy in cancer treatment.The cinobufacini injection is widely used in patients with moderate and advanced liver cancer in China.In the present study, we aimed to determine the effects of cinobufacini injection for this specific category of patients.A search for randomized control trials(RCTs) using cinobufacini was conducted in the PubMed, EMBASE, CENTRAL, and the other four major Chinese databases.The systematic review was performed according to the recommendations of the Cochrane collaboration, and the RevMan 5.3.software was used for statistical analysis.A random-effects model was used to perform the data.Risk ratios(RR) with corresponding 95% confidence interval were calculated according to Cochrane handbook.A total of 11 RCTs consisting of 728 patients were included.All of the trials demonstrated significantly improved total response rates, total response rates of Karnofsky Performance Score(KPS), 1-to 2-year survival rates, and quality of life in the intervention groups injected with cinobufacini.There was no statistically significant difference between the groups(cinobufacini versus no cinobufacini; cinobufacini plus transcatheter arterial chemoembolization(TACE) versus TACE only) in terms of the 6-month survival rate, clinical benefit rate and clinical benefit rate of KPS.This systematic review demonstrated the beneficial effects of cinobufacini injection in terms of total response rate and the 1-to 2-year survival rate in patients with moderate and advanced liver cancer.The efficacy for the cinobufacini injection group might be better than that of the control group for treatment of moderate and advanced liver cancer.Given that the majority of the trials were of low quality, more high-quality prospective RCTs with strict design in accordance with CONSORT for TCM are needed.展开更多
文摘目的探讨“基于膜解剖的胃后间隙入路”(我们称之为“欢乐间隙”)联合食管空肠自牵引后离断吻合技术(self-pulling and latter transection,SPLT)在全腹腔镜近端胃切除、双通道吻合术中的应用价值。方法2019年9月~2021年9月,对15例T1~2N0M0食管胃结合部肿瘤行3D全腹腔镜下近端胃切除、双通道吻合术。“欢乐间隙”为我们基于“膜解剖”理论提出的位于腹腔干左侧、胰腺上后缘的Gerota筋膜与胃背系膜之间的融合筋膜间隙,手术进入此间隙可快速完成胃后部分的分离并完成手术,术者感到愉悦,故称为“欢乐间隙”。使用SPLT技术行食管-空肠吻合。结果15例均顺利完成全腹腔镜手术。手术时间(237.5±55.3)min,术中出血量(84.7±28.3)ml,术后排气时间(2.1±0.4)d,术后进流质饮食时间(2.9±1.1)d,术后引流时间(6.4±0.9)d,总住院时间(15.1±2.1)d。术后病理腺癌11例,高级别上皮内瘤变4例,切缘均为阴性。术后肺部感染2例。随访1年,均未出现反流性食管炎及肿瘤复发,各营养指标变化差异无显著性(P>0.05)。结论“欢乐间隙”入路联合SPLT技术在全腹腔镜近端胃切除、双通道吻合术中安全可行。
文摘目的:探讨Src酪氨酸激酶抑制剂对人胃癌细胞SGC7901上皮-间质转变相关基因的作用及机制。方法:以Src酪氨酸激酶抑制剂作用前后的SGC7901细胞为研究对象,应用Western blot及real time PCR观察细胞内p-Src及上皮间质转变标志物E-钙黏素(E-cadherin)、β-连环蛋白(β-catenin)表达的变化,报告基因技术检测Snail在转录水平表达的变化。结果:Src酪氨酸激酶抑制剂可上调E-cadherin在mRNA和蛋白水平变化,下调β-catenin在mRNA和蛋白水平变化及Snail的启动子活性。结论:Src酪氨酸激酶抑制剂可抑制人胃癌细胞SGC7901上皮间质转变相关基因表达,其机制可能与其下调SGC7901细胞Snail的启动子活性有关。
基金Science and Technology Project of Putian University,China(Grant No.2013035)
文摘Cinobufacini, a compound extracted from bufo toad, is a traditional Chinese medicine(TCM) that has been shown to have efficacy in cancer treatment.The cinobufacini injection is widely used in patients with moderate and advanced liver cancer in China.In the present study, we aimed to determine the effects of cinobufacini injection for this specific category of patients.A search for randomized control trials(RCTs) using cinobufacini was conducted in the PubMed, EMBASE, CENTRAL, and the other four major Chinese databases.The systematic review was performed according to the recommendations of the Cochrane collaboration, and the RevMan 5.3.software was used for statistical analysis.A random-effects model was used to perform the data.Risk ratios(RR) with corresponding 95% confidence interval were calculated according to Cochrane handbook.A total of 11 RCTs consisting of 728 patients were included.All of the trials demonstrated significantly improved total response rates, total response rates of Karnofsky Performance Score(KPS), 1-to 2-year survival rates, and quality of life in the intervention groups injected with cinobufacini.There was no statistically significant difference between the groups(cinobufacini versus no cinobufacini; cinobufacini plus transcatheter arterial chemoembolization(TACE) versus TACE only) in terms of the 6-month survival rate, clinical benefit rate and clinical benefit rate of KPS.This systematic review demonstrated the beneficial effects of cinobufacini injection in terms of total response rate and the 1-to 2-year survival rate in patients with moderate and advanced liver cancer.The efficacy for the cinobufacini injection group might be better than that of the control group for treatment of moderate and advanced liver cancer.Given that the majority of the trials were of low quality, more high-quality prospective RCTs with strict design in accordance with CONSORT for TCM are needed.
